Jim Simons Akero Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$18.31 - $24.62 $441,270 - $593,342	24,100 New	24,100 $565,000
Q1 2023 May 12, 2023	BUY	$37.27 - $50.24 $3.78 Million - $5.09 Million	101,300 Added 149.85%	168,900 $6.46 Million
Q4 2022 Feb 13, 2023	BUY	$33.44 - $54.8 $117,039 - $191,800	3,500 Added 5.46%	67,600 $3.7 Million
Q3 2022 Nov 14, 2022	SELL	$10.15 - $34.05 $585,655 - $1.96 Million	-57,700 Reduced 47.37%	64,100 $2.18 Million
Q2 2022 Aug 12, 2022	BUY	$8.0 - $15.01 $549,600 - $1.03 Million	68,700 Added 129.38%	121,800 $1.15 Million
Q1 2022 May 13, 2022	BUY	$12.97 - $22.26 $688,707 - $1.18 Million	53,100 New	53,100 $753,000
Q1 2021 May 13, 2021	SELL	$24.04 - $34.19 $3.6 Million - $5.13 Million	-149,900 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$25.12 - $29.89 $2.86 Million - $3.4 Million	113,700 Added 314.09%	149,900 $3.87 Million
Q3 2020 Nov 13, 2020	BUY	$30.79 - $39.92 $52,835 - $68,502	1,716 Added 4.98%	36,200 $1.12 Million
Q2 2020 Aug 13, 2020	BUY	$19.25 - $26.76 $663,817 - $922,791	34,484 New	34,484 $859,000

190

73.8M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.45B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.